ACM
LLY icon

Ascendant Capital Management’s Eli Lilly LLY Stock Holding History

Ascendant Capital Management’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3,000
Closed -$1.1M – 71
2022
Q4 		$1.1M Buy
+3,000
New +$1.06M 3.28% 9
2022
Q3 		– Sell
-4,200
Closed -$1.36M – 33
2022
Q2 		$1.36M Buy
+4,200
New +$1.26M 4.02% 7

Other funds holding LLY

Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $84.5B AUM 11.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Ascendant Capital Management's LLY Position: Q1 2023 in Review

Ascendant Capital Management sold out of Eli Lilly (LLY) in Q1 2023, closing a stake of 3,000 shares — an estimated $1.1M sold.

Ascendant Capital Management first reported a position in LLY in Q2 2022 and held it in 2 quarters. The position peaked at $1.36M in Q2 2022. 2,614 funds tracked by Wall St. Rank hold LLY as of Q1 2023.

  • Ascendant Capital Management reported no remaining Eli Lilly position as of Q1 2023 after selling out during the quarter.
  • Ascendant Capital Management sold 3,000 Eli Lilly shares in Q1 2023, an estimated $1.1M.
  • Ascendant Capital Management first reported a position in Eli Lilly in Q2 2022 and held it in 2 quarters.
  • Ascendant Capital Management's Eli Lilly position peaked at $1.36M in Q2 2022.
  • 2,614 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2023.

Based on Ascendant Capital Management's 13F filing for Q1 2023, filed 15 May 2023.